Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07815964

Turkish Validity and Reliability of the Parkinson's Disease Neuropsychometric Dementia Assessment Questionnaire in Individuals With Parkinson's Disease

The aim of this study is to examine the validity and reliability of the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the Turkish PANDA, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable instrument for the assessment of cognitive impairment and dementia-related cognitive changes in Turkish-speaking individuals with Parkinson's disease.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

PARKINSON DISEASE (Disorder) Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

**Inclusion Criteria:**

  • Clinical diagnosis of Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • Age between 40 and 85 years
  • Mini-Mental State Examination score ≥ 24
  • Sufficient cognitive and communication ability to complete the assessments
  • Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department
  • Willingness to participate in the study and provide written informed consent

**Exclusion Criteria:**

  • Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder
  • Diagnosis of advanced dementia
  • Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension
  • Presence of a severe cardiovascular or respiratory condition
  • Presence of an additional orthopedic or neurological condition that may affect assessment performance
  • Severe visual or hearing impairment that may interfere with the assessments
  • Inability to cooperate adequately during the assessments

Treatment and study plan

Parkinson Neuropsychometric Dementia Assessment

Other

Participants will complete the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA) as part of the psychometric evaluation process. The PANDA will be administered according to standardized instructions to assess cognitive performance in individuals with Parkinson's disease. To evaluate test-retest reliability, the Turkish PANDA will be re-administered to a subgroup of participants after a predefined interval under similar conditions. No therapeutic intervention will be provided as part of this methodological validation study.

Primary outcomes

  1. Parkinson Neuropsychometric Dementia Assessment (PANDA) Total Score

    Time frame: [Time Frame: Baseline (at the time of PANDA administration)]

    Cognitive performance will be assessed using the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. The PANDA is a brief cognitive screening instrument specifically developed for Parkinson's disease and includes tasks assessing learning and memory, verbal fluency, visuospatial processing, working memory, and delayed recall.

    The PANDA total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The psychometric properties of the Turkish version, including internal consistency, test-retest reliability, and construct validity, will be evaluated.

Secondary outcomes

  1. Montreal Cognitive Assessment (MoCA) Total Score

    Time frame: [Time Frame: Baseline (at the time of cognitive assessment)]

    Global cognitive performance will be assessed using the Montreal Cognitive Assessment (MoCA), a widely used cognitive screening tool that evaluates multiple cognitive domains, including attention, executive functions, memory, language, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    MoCA scores will be used to evaluate the convergent construct validity of the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA).

  2. Mini-Mental State Examination (MMSE) Total Score

    Time frame: [Time Frame: Baseline (at the time of cognitive assessment)]

    General cognitive status will also be assessed using the Mini-Mental State Examination (MMSE), which evaluates orientation, registration, attention and calculation, recall, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    MMSE scores will be examined in relation to PANDA scores to further assess the convergent construct validity of the Turkish version of the PANDA.

Study contacts

Contact information is provided by the study sponsor or research team.

Nuray Alaca Alaca, Prof. Dr

CONTACT

[email protected]

05324251290

Sponsors and collaborators

Lead sponsor

Acibadem University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 11, 2026
Registry last updated
Sep 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.